Alzheimer’s drugs continue to be rejected by NICE over cost

Getty/selvanegra

By Erin Dean

Ongoing concerns over cost and evidence gaps have prompted the NHS spending watchdog to continue to recommend against two new drugs for Alzheimer’s disease.

But the National Institute for Health and Care Excellence (NICE) is calling for more evidence on donanemab and lecanemab before publishing its final draft guidance.